{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine-primed+T-cells&page=2", "query": { "intervention": "Vaccine-primed T-cells", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 28, "total_pages": 3, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine-primed+T-cells&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Vaccine-primed+T-cells&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T09:46:24.102Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT04776317", "title": "Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "ChAdV68-S", "type": "BIOLOGICAL" }, { "name": "ChAdV68-S-TCE", "type": "BIOLOGICAL" }, { "name": "SAM-LNP-S", "type": "BIOLOGICAL" }, { "name": "SAM-LNP-S-TCE", "type": "BIOLOGICAL" }, { "name": "Sodium Chloride, 0.9%", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "99 Years", "sex": "ALL", "summary": "18 Years to 99 Years" }, "enrollment_count": 81, "start_date": "2021-03-25", "completion_date": "2023-09-15", "has_results": true, "last_update_posted_date": "2025-05-16", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 4, "location_summary": "Decatur, Georgia • St Louis, Missouri • Houston, Texas + 1 more", "locations": [ { "city": "Decatur", "state": "Georgia" }, { "city": "St Louis", "state": "Missouri" }, { "city": "Houston", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT04776317" }, { "nct_id": "NCT00490529", "title": "Phase 1-2 of a CpG-Activated Whole Cell Vaccine Followed by Autologous Immunotransplant for MCL", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma, Mantle-Cell" ], "interventions": [ { "name": "CpG-MCL vaccine", "type": "BIOLOGICAL" }, { "name": "PF-3512676", "type": "BIOLOGICAL" }, { "name": "Vaccine-primed T-cells", "type": "PROCEDURE" }, { "name": "Autologous hematopoietic stem cell transplant (HSCT)", "type": "PROCEDURE" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Standard induction chemotherapy", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Filgrastim", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "PROCEDURE", "DRUG" ], "sponsor": "Ronald Levy", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "21 Years to 70 Years" }, "enrollment_count": 59, "start_date": "2009-08", "completion_date": "2017-12-14", "has_results": true, "last_update_posted_date": "2020-01-13", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 1, "location_summary": "Stanford, California", "locations": [ { "city": "Stanford", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00490529" }, { "nct_id": "NCT00499577", "title": "Stem Cell Transplant, Chemotherapy, and Biological Therapy in Treating Patients With High-Risk or Refractory Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "CMV pp65 peptide", "type": "BIOLOGICAL" }, { "name": "hTERT I540/R572Y/D988Y multipeptide vaccine", "type": "BIOLOGICAL" }, { "name": "pneumococcal polyvalent vaccine", "type": "BIOLOGICAL" }, { "name": "survivin Sur1M2 peptide vaccine", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Maryland Greenebaum Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 56, "start_date": "2006-12", "completion_date": null, "has_results": false, "last_update_posted_date": "2014-01-10", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00499577" }, { "nct_id": "NCT07374029", "title": "Adoptive T Cell Therapy With DC/AML Fusion Vaccine Plus Decitabine and Venetoclax in AML", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia", "Acute Myeloid Leukemia, in Relapse" ], "interventions": [ { "name": "DC/AML Fusion Vaccine", "type": "BIOLOGICAL" }, { "name": "T-Cell Therapy", "type": "BIOLOGICAL" }, { "name": "Decitabine", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" }, { "name": "GM-CSF", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "David Avigan", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 30, "start_date": "2026-02-12", "completion_date": "2030-10-01", "has_results": false, "last_update_posted_date": "2026-05-05", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT07374029" }, { "nct_id": "NCT01245673", "title": "Combination Immunotherapy and Autologous Stem Cell Transplantation for Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Myeloma" ], "interventions": [ { "name": "Prevnar- Pneumococcal Conjugate Vaccine (PCV)", "type": "BIOLOGICAL" }, { "name": "Activated/costimulated autologous T-cell", "type": "OTHER" }, { "name": "Revlamid® (Lenalidomide)", "type": "DRUG" }, { "name": "MAGE-A3/GM-GSF, Hiltonol® (Poly-ICLC)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "OTHER", "DRUG" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 28, "start_date": "2011-05-10", "completion_date": "2018-12", "has_results": true, "last_update_posted_date": "2020-04-06", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT01245673" }, { "nct_id": "NCT03091660", "title": "S1602: Different Strains of BCG With or Without Vaccine in High Grade Non- Muscle Invasive Bladder Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Stage 0 Bladder Urothelial Carcinoma", "Stage 0is Bladder Urothelial Carcinoma", "Stage I Bladder Urothelial Carcinoma" ], "interventions": [ { "name": "BCG Solution", "type": "BIOLOGICAL" }, { "name": "BCG Tokyo-172 Strain Solution", "type": "BIOLOGICAL" }, { "name": "BCG Tokyo-172 Strain Vaccine", "type": "BIOLOGICAL" }, { "name": "Laboratory Biomarker Analysis", "type": "OTHER" } ], "intervention_types": [ "BIOLOGICAL", "OTHER" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 1000, "start_date": "2017-02-24", "completion_date": "2026-06-15", "has_results": false, "last_update_posted_date": "2026-03-23", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 174, "location_summary": "Mobile, Alabama • Gilbert, Arizona • Phoenix, Arizona + 111 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Duarte", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03091660" }, { "nct_id": "NCT06564623", "title": "Targeting Driver Oncogenes With a Peptide Vaccine Plus Durvalumab and Tremelimumab for Patients With Biliary Tract Cancers (BTC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Biliary Tract Cancers" ], "interventions": [ { "name": "mBTC vax [0.3 - 2.4 mg peptide + 0.5 mg Poly-ICLC (Hiltonol)]", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" }, { "name": "Tremelimumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 25, "start_date": "2025-05-27", "completion_date": "2029-03", "has_results": false, "last_update_posted_date": "2026-05-08", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT06564623" }, { "nct_id": "NCT06514898", "title": "Adoptive T Cell Therapy, DC Vaccines, and Hematopoietic Stem Cells Combined With Immune checkPOINT Blockade in Patients With Medulloblastoma", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Group 3 Medulloblastoma", "Recurrent Group 4 (Non-SHH/Non-WNT) Medulloblastoma" ], "interventions": [ { "name": "TTRNA-DC vaccines with GM-CSF", "type": "BIOLOGICAL" }, { "name": "TTRNA-xALT", "type": "BIOLOGICAL" }, { "name": "Td vaccine", "type": "DRUG" }, { "name": "autologous HSCs", "type": "BIOLOGICAL" }, { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "University of Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "4 Years", "maximum_age": "30 Years", "sex": "ALL", "summary": "4 Years to 30 Years" }, "enrollment_count": 12, "start_date": "2025-05-05", "completion_date": "2028-12-01", "has_results": false, "last_update_posted_date": "2026-08-07", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 2, "location_summary": "Washington D.C., District of Columbia • Gainesville, Florida", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06514898" }, { "nct_id": "NCT04080245", "title": "Functional Consequences of T-bet Expression in Flu-specific Memory B Cells After Live Attenuated Influenza Vaccine (LAIV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Influenza, Human" ], "interventions": [ { "name": "Treatment Group Live Attenuated Flu Vaccine (LAIV)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Alabama at Birmingham", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "ALL", "summary": "18 Years to 50 Years" }, "enrollment_count": 10, "start_date": "2019-11-15", "completion_date": "2025-06-01", "has_results": false, "last_update_posted_date": "2025-06-11", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 1, "location_summary": "Birmingham, Alabama", "locations": [ { "city": "Birmingham", "state": "Alabama" } ], "official_url": "https://clinicaltrials.gov/study/NCT04080245" }, { "nct_id": "NCT00834665", "title": "Phase I/II Clinical Trial Combining hTERT Tumor Vaccine & Autologous T Cells in Patients With Advanced Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "hTERT vaccine, GM-CSF, PCV, T cell infusion", "type": "BIOLOGICAL" }, { "name": "GM-CSF, PCV, T cell infusion", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "University of Pennsylvania", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 59, "start_date": "2006-12", "completion_date": "2017-12", "has_results": false, "last_update_posted_date": "2019-10-23", "last_synced_at": "2026-10-02T09:46:24.102Z", "location_count": 2, "location_summary": "Baltimore, Maryland • Philadelphia, Pennsylvania", "locations": [ { "city": "Baltimore", "state": "Maryland" }, { "city": "Philadelphia", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00834665" } ] }